Not for distribution to U.S. news wire services or dissemination in the United States

Read more here:
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company

A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors’ earn-out is in Firefly’s common stock. The complete corrected press release follows:

More:
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of...

Basel, Switzerland, 6 May 2025 – Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces that recruitment is completed in the National Institutes of Health (NIH) -sponsored Phase 2b EN21-01 trial (ClinicalTrials.gov identifier NCT05480228). The study evaluates Novaremed’s non-opioid investigational drug NRD.E1 for the treatment of chronic pain associated with diabetic peripheral neuropathy, and is funded by the NIH Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. Topline Phase 2b data readout is expected in Q4 2025.

See original here:
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with...

Basel, 06 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its Elecsys® PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD). The test, developed in partnership with Nordic Bioscience, offers clinicians a simple and efficient method of identifying patients with liver fibrosis of varying severity, enabling timely intervention and appropriate management of the disease.

Here is the original post:
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

May 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.

View original post here:
argenx to Present at BofA Securities 2025 Health Care Conference

PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew.

Excerpt from:
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio

Continue reading here:
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy

Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward

See the article here:
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations

Read more:
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa

CAMBRIDGE, United Kingdom and SINGAPORE, April 22, 2025 (GLOBE NEWSWIRE) -- Cambridge’s DIOSynVax and Singapore’s ACM Biolabs will be jointly developing a next-generation universal bird flu vaccine with the potential for mucosal delivery to combat the next pandemic. This bilateral project is supported by Innovate UK1 and Enterprise Singapore2, as part of the UK-Singapore Collaborative R&D Call.

Link:
Cambridge’s DIOSynVax and Singapore’s ACM Biolabs to Advance Pandemic-Ready Universal Bird Flu Vaccine with International Support

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro’s deep learning and ML programs with Nebul’s high-performance computing (“HPC”) built on the latest platform to accelerate biomarker discovery and next-generation diagnostics.

Read the original here:
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

BANGKOK, April 22, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission on April 22, 2025 Eastern Time. The annual report can be accessed on the Company’s investor relations website at https://investors.newgenivf.com.

Originally posted here:
NewGen Filed 2024 Annual Report on Form 20-F

AGOURA HILLS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a biotechnology company focused on nanomedicine and RNA-based therapeutics, announced today that its Chairman and CEO, Dr. Vuong Trieu, will deliver a keynote presentation at the 21st Annual Congress of International Drug Discovery Science & Technology (IDDST-Europe), scheduled for June 18-20, 2025, in Stockholm, Sweden.

Continue reading here:
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Andrew Taylor will assume the role as EVP of Food & Beverage Biosolutions at Novonesis.

Link:
Andrew Taylor joins Novonesis’ Executive Leadership Team

MESA, Ariz., April 22, 2025 (GLOBE NEWSWIRE) -- Elite Clinical Network, a leading nationwide integrated clinical research site organization, has announced a strategic partnership with HealthyU Clinics, a digitally enabled primary care provider focused on delivering accessible, patient-centered healthcare.

Follow this link:
Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research

VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Convertible Debentures will be offered in units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “Offering”). The Company plans to use the proceeds of the Offering for general corporate purposes.

More:
Sirona Biochem Announces Debenture Financing

/ Not for distribution to U.S. news wire services or for dissemination in the United States /

Read more from the original source:
Digicann Ventures Provides Update Regarding Proposed RTO Transaction

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Read more from the original source:
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

-- Poster to be presented at OARSI World Congress on Osteoarthritis --BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, April 24-27.

Read this article:
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe...

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

More:
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones